Redhill Biopharma Ltd (NASDAQ: RDHL) — Healthcare · Share Price, Chart & Market Data
About: RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $0.83 (-2.21%)
RDHLRedhill Biopharma Ltd
Loading watchlist status…
Trade RDHL now
Redhill Biopharma Ltd share price
RDHL price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
23 Apr, 2:14 pm GMT+0
RDHL price performance
5.532%
5D
-5.372%
1M
-19.621%
YTD
-63.04%
1Y
RDHL price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
23 Apr, 2:14 pm GMT+0
RDHL details
RDHL Market Signals